Return to News & Events 

 

Immunetics Awarded $2.4 Million NIH Grant for Clinical Trials of New Blood Test for Chagas’ Disease

BOSTON, MASSACHUSETTS, May 3, 2011 – Immunetics, Inc. today announced it has been awarded a $2.4 million, 3-year Phase II SBIR grant by the National Institute of Allergy and Infectious Diseases, a division of the National Institutes of Health (NIH), to support clinical trials of the company's new confirmatory test for Chagas’ disease, a serious and potentially fatal parasitic infection.

Chagas' disease is endemic in large parts of Latin America, where it affects up to 11 million people, and has emerged in the U.S., where more than 300,000 people are infected, according to the Centers for Disease Control and Prevention. The disease is difficult to diagnose, and is often silent for years before clinical symptoms appear. During this time, carriers can pass on the parasite through blood donations and infect transfusion recipients.

Existing screening tests that detect antibodies to the parasite are frequently inaccurate. A complex method called radioimmunoprecipitation (RIPA) is sometimes used to confirm screening test results, but is beyond the reach of most laboratories. There are no FDA-approved confirmatory test methods.

Immunetics’ test, called an immunoblot, detects antibodies to the parasite and is based on the same technology used in confirmatory tests for HIV and several other bloodborne infections. Data presented by Immunetics at meetings in 2010 of the American Association of Blood Banks and the American Society of Tropical Medicine and Hygiene showed the immunoblot test to be as accurate as RIPA in preliminary studies, said Dr. Andrew Levin, president and scientific director, Immunetics.

"The new NIH grant will enable Immunetics to undertake a full-scale clinical trial to obtain data to submit to the FDA for approval of the immunoblot as a confirmatory test. Immunetics will undertake the studies with collaborators at Blood Systems Research Institute, the American Red Cross, and the Centers for Disease Control and Prevention," Levin said.

“This grant award gives us the opportunity to take our Chagas’ immunoblot test through the clinical studies needed to establish its validity as a confirmatory test. We are very grateful for NIH support for this project, which will allow us to bring forward a practical solution to one part of the growing public health and blood safety problem that Chagas’ disease presents in the U.S. and Latin America," he said.

* * * * * * *

Immunetics (www.immunetics.com) offers state-of-the-art assay technology for infectious disease diagnosis and pathogen detection. For over 10 years, the company has been a leading innovator of tests for bacterial, viral, and parasitic diseases. Immunetics produces and markets a range of infectious disease assay kits and instruments.  Its mission is better, cost-efficient care through more accurate diagnosis. Immunetics is headquartered in Boston, Mass. Follow Immunetics on Twitter at http://twitter.com/immunetics.

News
FDA Approves Apheresis Platelet Claims for Immunetics' BacTx Rapid Test for Bacterial Contamination
Read more...
View Full Article
Leading Physicians to Discuss “Advances in Bacterial Testing of Platelets: BacTx Field Experience” at American Association of Blood Banks (AABB) Annual Meeting
Read more...
View Full Article
Immunetics Receives $3.7 Million NIH Contract for Babesia Blood Screening Test
Read more...
View Full Article
Immunetics Receives FDA Clearance for BacTx Rapid Test for Bacterial Contamination of Platelets
Read more...
View Full Article
AIM International Business Council (AIM-IBC) Announces 2012 Global Trade Award Winners
Read more...
View Full Article
Immunetics, Inc. to Present Novel, Rapid Test for Bacterial Contamination of Platelets at American Association of Blood Banks (AABB) Annual Meeting
Read more...
View Full Article
MassDevelopment Loans Allow Immunetics to Manufacture & Launch BacTx Test for Bacterial Contamination in Blood Platelet Transfusions
Read more...
View Full Article
Immunetics Receives $500,000 from Massachusetts Life Sciences Center to Commercialize BacTx® Test for Bacterial Contamination in Blood Platelet Transfusions
Read more...
View Full Article
Immunetics Awarded $2.4 Million NIH Grant for Clinical Trials of New Blood Test for Chagas’ Disease
Read more...
View Full Article
Immunetics Featured at Boston Startup America Event
Read more...
View Full Article
National Institutes of Health awards two grants for infectious disease tests
Read more...
View Full Article
National Institutes of Health awards $2.5 million  grant for new bacterial test
Read more...
QuickELISA™ Anthrax-PA Kit first to win FDA approval for clinical diagnosis
Read more...
View Full Article